Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $104.79 USD
Change Today -4.28 / -3.92%
Volume 1.4M
ALNY On Other Exchanges
As of 2:37 PM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

John M. Maraganore M.D., Ph.D.

Chief Executive Officer and Executive Director,Alnylam Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 172 board members in 7 different organizations across 10 different industries.

See Board Relationships
As of Fiscal Year 2014


Dr. John M. Maraganore, Ph.D., has been the Chief Executive Officer at Alnylam Pharmaceuticals Inc. since December 2002. Dr. Maraganore has been a Venture Partner at Third Rock Ventures, LLC since May 14, 2013. He joined Third Rock Ventures, LLC to participate in a limited capacity guiding strategy for it and its portfolio companies. Dr. Maraganore served as the President of Alnylam Pharmaceuticals Inc. from December 2002 to December 2007. From April 2000 to December ...

Read Full Background

Corporate Headquarters*

300 Third Street
Cambridge, Massachusetts 02142

United States

Phone: 617-551-8200
Fax: 617-551-8101

Board Members Memberships*

Chief Executive Officer and Executive Director
Director and Member of Compensation Committee
Director, Member of Audit Committee and Member of Compensation Committee
Director and Member of Compensation Committee


The University of Chicago
The University of Chicago
The University of Chicago

Other Affiliations*

Annual Compensation*

Total Annual Compensation$689,585

Stock Options*

All Other Compensation$7,596
Exercised Options424,247
Exercised Options Value$25,275,188
Exercisable Options1,032,008
Unexercisable Options225,000
Total Value of Options$25,275,188
Total Number of Options1,731,255

Total Compensation*

Total Annual Cash Compensation$1,141,181
Total Short Term Compensation$689,585
Other Long Term Compensation$7,596
Total Calculated Compensation$1,141,181
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALNY:US $104.67 USD -4.40


Stanley T. Crooke M.D., Ph.D.Founder, Executive Chairman, Chief Executive Officer, President, Chairman of Science/Medical Committee and Member of Agenda Committee
Isis Pharmaceuticals, Inc.
Edward M. Kaye M.D., Ph.D.Interim Chief Executive Officer, Chief Medical Officer and Senior Vice President
Sarepta Therapeutics, Inc.
Mark W. Schwartz Ph.D.Chief Executive Officer, President, Director and Member of Ad Hoc (Strategy, Pricing, Etc) Committee
Galena Biopharma, Inc.
Mark Joseph Murray Ph.D.Chief Executive Officer, President and Director
Arbutus Biopharma Corporation
Paul C. Grint M.D.Chief Executive Officer, President and Director
Regulus Therapeutics Inc.
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALNYLAM PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at